TATUM Bioscience is a biotechnology company developing next-generation immunotherapies using engineered bacteriophage nanofilaments. Their modular synthetic biology platform creates multimodal nanofilaments that elicit comprehensive antitumor immune responses, aiming for effective tumor clearance.
Engineered Bacteriophage product pipeline:
- TAT003: combines PD-L1 blockade, interleukin-2 receptor stimulation.
- TLR9: agonistic activities, demonstrating significant efficacy in preclinical cancer models.
